SAT0382 Palace 4, A Phase 3, Randomized, Controlled TRIAL of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-Term (52-WEEK) Improvements in Physical Function

A Wells,A.O Adebajo,P Bird,A.J Kivitz,K Shah,C Edwards,C Hu,R.M Stevens,J.A Aelion

doi:10.1136/annrheumdis-2014-eular.1096

SAT0382 Palace 4, A Phase 3, Randomized, Controlled TRIAL of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-Term (52-WEEK) Improvements in Physical Function

A Wells, A.O Adebajo + Show 7 more

https://doi.org/10.1136/annrheumdis-2014-eular.1096

Copy DOI

Export

Save

Cite

Journal: Annals of the Rheumatic Diseases	Publication Date: Jun 1, 2014
Citations: 2

Affiliation: University of Sheffield, Bristol-Myers Squibb (Switzerland), University Hospital Southampton NHS Foundation Trust

#Minimum Clinically Important Difference #SF-36v2 Physical Component Summary #Change In HAQ-DI #SF-36v2 Physical Function #Physical Component Summary #Improvements In Physical Function #PBO-controlled Period #Meaningful Improvements In Physical Function #Active PsA #Proportion Of Pts

Abstract
Full-Text
Similar Papers

Abstract

Listen

BackgroundApremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to regulate inflammatory mediators. PALACE 4 compared APR efficacy/safety with placebo (PBO) in patients (pts) with active PsA who were DMARD-naïve.ObjectivesEvaluate...

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

SAT0382 Palace 4, A Phase 3, Randomized, Controlled TRIAL of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-Term (52-WEEK) Improvements in Physical Function